Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study

The aim of this study was to assess the independent contributions of plasma levels of lipoprotein(a) (Lp(a)), Lp(a) cholesterol, and of apo(a) isoform size to prospective coronary heart disease (CHD) risk. Plasma Lp(a) and Lp(a) cholesterol levels, and apo(a) isoform size were measured at examination cycle 5 in subjects participating in the Framingham Offspring Study who were free of CHD. After a mean follow-up of 12.3 years, 98 men and 47 women developed new CHD events. In multivariate analysis, the hazard ratio of CHD was approximately two-fold greater in men in the upper tertile of plasma Lp(a) levels, relative to those in the bottom tertile (P < 0.002). The apo(a) isoform size contributed only modestly to the association between Lp(a) and CHD and was not an independent predictor of CHD. In multivariate analysis, Lp(a) cholesterol was not significantly associated with CHD risk in men. In women, no association between Lp(a) and CHD risk was observed. Elevated plasma Lp(a) levels are a signifi cant and independent predictor of CHD risk in men. The assessment of apo(a) isoform size in this cohort does not add signifi cant information about CHD risk. In addition, the cholesterol content in Lp(a) is not a signifi cant predictor of CHD risk. Lamon-Fava, S., S. M. Marcovina, J. J. Albers, H. Kennedy, C. DeLuca, C. C. White, L. A. Cupples, J. R. McNamara, L. J. Seman, V. Bongard, and E. J. Schaefer. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J. Lipid Res. 2011. 52: 1181-1187.